These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38771635)

  • 41. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
    Erstad BL
    Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of hepatorenal syndrome and associated outcomes: a systematic reviews.
    Roozbeh J; Ezzatzadegan Jahromi S; Rezazadeh MH; Hamidianjahromi A; Malekmakan L
    BMJ Open Gastroenterol; 2024 Apr; 11(1):. PubMed ID: 38631807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
    J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
    N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
    Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
    Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].
    Xing F; Li S; Zhang JJ; Sun CY; Huang JR; Gao ZL; Zhu TT; Zhao Q; Zhang H; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):982-988. PubMed ID: 31941260
    [No Abstract]   [Full Text] [Related]  

  • 47. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
    Solà E; Cárdenas A; Ginès P
    Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.
    Boyer TD; Sanyal AJ; Garcia-Tsao G; Blei A; Carl D; Bexon AS; Teuber P;
    J Hepatol; 2011 Aug; 55(2):315-21. PubMed ID: 21167235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis.
    Gow PJ; Sinclair M; Thwaites PA; Angus PW; Chapman B; Terbah R; Testro AG
    Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):206-212. PubMed ID: 32976193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment.
    Belcher JM
    Med Clin North Am; 2023 Jul; 107(4):781-792. PubMed ID: 37258014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early Versus Standard Initiation of Terlipressin for Acute Kidney Injury in ACLF: A Randomized Controlled Trial (eTerli Study).
    Jindal A; Singh H; Kumar G; Arora V; Sharma MK; Maiwall R; Rajan V; Tewathia HV; Vasishtha C; Sarin SK
    Dig Dis Sci; 2024 Jun; 69(6):2204-2214. PubMed ID: 38637454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
    Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward.
    Belcher JM; Parada XV; Simonetto DA; Juncos LA; Karakala N; Wadei HM; Sharma P; Regner KR; Nadim MK; Garcia-Tsao G; Velez JCQ; Parikh SM; Chung RT; Allegretti AS;
    Am J Kidney Dis; 2022 May; 79(5):737-745. PubMed ID: 34606933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.
    Hinz M; Wree A; Jochum C; Bechmann LP; Saner F; Gerbes AL; Gerken G; Canbay A
    Ann Hepatol; 2013; 12(1):92-9. PubMed ID: 23293199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration.
    Gerbes AL; Huber E; Gülberg V
    Gastroenterology; 2009 Sep; 137(3):1179; author reply 1179-81. PubMed ID: 19631603
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
    Premkumar M; Kajal K; Reddy KR; Izzy M; Kulkarni AV; Duseja AK; Sihag KB; Divyaveer S; Gupta A; Taneja S; De A; Verma N; Rathi S; Bhujade H; Chaluvashetty SB; Roy A; Kumar V; Siddhartha V; Singh V; Bahl A
    Hepatology; 2024 May; 79(5):1048-1064. PubMed ID: 37976391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of continuous versus intermittent infusions of terlipressin for the control of acute variceal bleeding in patients with portal hypertension: An open-label randomized controlled trial.
    Jha SK; Mishra M; Jha A; Dayal VM
    Indian J Gastroenterol; 2018 Jul; 37(4):313-320. PubMed ID: 30132224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
    Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
    J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.